Publications
Detailed Information
Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Moon Jung | - |
dc.contributor.author | Han, Eui Seok | - |
dc.contributor.author | Kim, JaeWoo | - |
dc.contributor.author | Kim, Tae-Woo | - |
dc.date.accessioned | 2012-06-29T04:11:23Z | - |
dc.date.available | 2012-06-29T04:11:23Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.citation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS; Vol.26 1; 49-54 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77903 | - |
dc.description.abstract | Purpose: To investigate whether bevacizumab may be delivered into the anterior chamber after subconjunctival administration and its pharmacokinetics in aqueous humor. Methods: The right eye of 33 rabbits received subconjunctival injection of 2.5 mg of subconjunctival bevacizumab. Three rabbits were sacrificed at each of the following time points: 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168 h after the injection. Bevacizumab concentrations were measured in aqueous fluid of injected and uninjected eyes and serum using enzyme-linked immunosorbent assay. Results: Bevacizumab was first detected in the aqueous humor of the injected eye at 12 h after the subconjunctival injection. A peak concentration of 70.59 +/- 26.01 ng/mL was achieved at 36 h. Bevacizumab was also detected in the serum and aqueous humor of the uninjected contralateral eye. The concentration in the aqueous humor of the injected eye was lower than in the serum and higher than in the aqueous humor of the uninjected contralateral eye at all time points. Elimination of bevacizumab from the serum and aqueous humor of injected and uninjected eye paralleled with half-life of 57.78 +/- 13.75 h, 27.64 +/- 1.95 h and 28.05 +/- 2.55 h, respectively. Conclusions: We demonstrated that bevacizumab can be delivered into anterior chamber by single subconjunctival injection. Further study is needed to assess whether subconjunctival bevacizumab is clinically useful in patients with neovascular glaucoma. | - |
dc.language.iso | en | - |
dc.publisher | MARY ANN LIEBERT INC | - |
dc.title | Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김문정 | - |
dc.contributor.AlternativeAuthor | 한의석 | - |
dc.contributor.AlternativeAuthor | 김재우 | - |
dc.contributor.AlternativeAuthor | 김태우 | - |
dc.identifier.doi | 10.1089/jop.2009.0022 | - |
dc.citation.journaltitle | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.description.citedreference | Arevalo JF, 2009, EYE, V23, P117, DOI 10.1038/sj.eye.6702980 | - |
dc.description.citedreference | Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8 | - |
dc.description.citedreference | Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036 | - |
dc.description.citedreference | Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012 | - |
dc.description.citedreference | Rensch F, 2008, OPHTHAL SURG LAS IM, V39, P182 | - |
dc.description.citedreference | Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031 | - |
dc.description.citedreference | Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936 | - |
dc.description.citedreference | BATIOGLU F, 2008, INT OPHTHALMOL, V28, P59, DOI 10.1007/s10792-007-9105-2 | - |
dc.description.citedreference | Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012 | - |
dc.description.citedreference | Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038 | - |
dc.description.citedreference | Scappaticci FA, 2007, J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/cjm086 | - |
dc.description.citedreference | Yazdani S, 2007, J GLAUCOMA, V16, P437 | - |
dc.description.citedreference | Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017 | - |
dc.description.citedreference | Vatavuk Z, 2007, EUR J OPHTHALMOL, V17, P269 | - |
dc.description.citedreference | Iliev ME, 2006, AM J OPHTHALMOL, V142, P1054 | - |
dc.description.citedreference | Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025 | - |
dc.description.citedreference | Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064 | - |
dc.description.citedreference | Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433 | - |
dc.description.citedreference | Mason JO, 2006, AM J OPHTHALMOL, V142, P685 | - |
dc.description.citedreference | Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161 | - |
dc.description.citedreference | Grisanti S, 2006, AM J OPHTHALMOL, V142, P158 | - |
dc.description.citedreference | Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352 | - |
dc.description.citedreference | Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112 | - |
dc.description.citedreference | Hurwitz H, 2004, NEW ENGL J MED, V350, P2335 | - |
dc.description.citedreference | WANG Y, 2004, ANGIOGENESIS, V7, P335 | - |
dc.description.citedreference | Kim TW, 2002, INVEST OPHTH VIS SCI, V43, P1809 | - |
dc.description.citedreference | Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186 | - |
dc.description.citedreference | JARVINEN T, 1995, ADV DRUG DELIV REV, V16, P16 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.